The Young Mania Rating Scale (YMRS) is an 11-item, clinician-rated measure of the severity of manic symptoms over the previous 48 hours. Its items cover the core manic syndrome - elevated mood, increased energy and activity, sexual interest, sleep, irritability, speech rate and amount, flight of ideas, grandiose or disordered thought content, aggressive behaviour, appearance, and insight. Ratings combine the patient's report of the past two days with the clinician's observation during the interview, with the emphasis on observation.
Four items - irritability, speech, thought content and disruptive-aggressive behaviour - are scored 0–8 with double weighting, while the remaining seven are scored 0–4. The double-weighted items were chosen deliberately: they can still be rated from observation when a severely manic patient cannot or will not cooperate with an interview. The total ranges from 0 to 60; higher scores mean more severe mania. It is a severity and monitoring instrument, not a diagnostic one.
02 - Origin & purpose
Where it comes from.
Young, Biggs, Ziegler and Meyer published the scale in the British Journal of Psychiatry in 1978, at a time when mania lacked a practical severity measure - existing scales were either too long for repeated inpatient use or too narrow to capture the syndrome. The YMRS was validated on inpatient ratings and designed to be completed in a 15–30 minute interview, with sensitivity to change built in so it could track treatment response across days.
It became, and remains, the default mania outcome measure in clinical trials - essentially every modern trial of antimanic treatment reports YMRS change - and a standard tool on inpatient units, including Danish and other Scandinavian services, for following acute mania through treatment. Its natural companions are a depression scale (mania rating says nothing about depressive symptoms) and, in psychosis, the PANSS.
03 - Scoring & cutoffs
How scoring works.
Each item is rated from anchored descriptions, seven items on 0–4 and four double-weighted items on 0–8, and the total is a simple sum from 0 to 60. The assessment window is the past 48 hours, weighted toward what the clinician observes in the interview. Conventions from the trial literature give the numbers meaning: studies typically require a YMRS of 20 or more for entry into acute mania trials, and define remission as a score of 12 or below (some use stricter thresholds). Severity banding between those anchors is approximate - the YMRS was built to measure change, not to classify.
Score
Severity
Interpretation
0–12
Remission range
Remission range commonly used in research.
13–19
Minimal to mild
Minimal to mild manic symptoms.
20–25
Moderate
Moderate - typical entry threshold for mania treatment trials.
26–60
Severe
Severe manic symptoms.
04 - Validation evidence
How well it performs.
The original 1978 study reported inter-rater reliability of 0.93 for the total score, with item-level agreement also high - a strength that has held up in later work and translations. Concurrent validity against other mania measures ranges from 0.71 to 0.89, and the scale demonstrated sensitivity to clinical change in its original inpatient validation, which is why it became the standard trial endpoint. Later psychometric work (e.g. the EMBLEM cohort analyses) has examined severity thresholds and clinically meaningful change, supporting the ≥20 trial-entry convention. Its main measured weaknesses are at the mild end: it discriminates less well among hypomanic states, and self-report versions correlate only moderately with clinician ratings.
0.93
Inter-rater reliability for the total score in the original validation (Young et al., 1978)
0.71–0.89
Concurrent validity against other mania rating scales (Young et al., 1978)
≥20
Typical minimum score for entry into acute mania treatment trials
48 h
Assessment window, combining patient report and interview observation
05 - How it compares
How it compares to the alternatives.
Instrument
Items
Time
When to reach for it
YMRS
11 items
15–30 min
Clinician-rated severity and monitoring of acute mania; the standard trial endpoint.
Global severity anchor alongside the YMRS in trials and clinics.
06 - When to use it
Right tool, wrong tool.
Reach for it when
-Rating severity of acute mania on inpatient units, including patients too unwell to cooperate fully (four items rate from observation)
-Monitoring antimanic treatment response over days to weeks
-Research and audits needing the standard mania outcome measure
-Young patients - it is widely used in adolescent mania, though anchors were written for adults
Reach for something else when
-Diagnosing bipolar disorder - it rates severity in patients already assessed as manic
-Detecting depression - pair it with MADRS or HAM-D; the YMRS is blind to the depressive pole
-Screening outpatients for hypomania - a self-report screen such as the ASRM or MDQ fits better
-Self-administration - it is a clinician interview; self-report adaptations are not equivalent
07 - Confidence & precision
Reading the score with care.
With inter-rater reliability of 0.93 under study conditions, the YMRS is one of the more precise clinician-rated instruments, but routine-practice agreement depends on anchor familiarity. The trial literature treats shifts of several points as meaningful; movement across the remission boundary (≤12) or the trial-entry boundary (≥20) is more informative than small within-band changes. Rate at consistent times of day where possible - manic symptoms fluctuate.
08 - Limitations
What it cannot tell you.
The YMRS says nothing about depression, so used alone it misses mixed states - always pair it in bipolar monitoring. Its anchors were written for adult inpatients in the 1970s; irritability and disruptive behaviour weigh heavily, which can inflate scores in agitated but non-manic patients. It discriminates poorly at the hypomanic end. Administration requires training and clinical familiarity with mania. And the 48-hour window means scores can swing with the day sampled. Finally, its copyright status limits electronic redistribution: services embedding it in systems should confirm permissions with the publisher.
See how Aisel removes friction where it costs most. A 20-minute walkthrough tailored to your clinic.
We value your privacy
We use cookies to analyse site usage and improve your experience. Analytics and embedded media (e.g. YouTube) only load if you accept. Read our cookie policy.